Solstice Shares Climb 12.8% after $14.5 Billion Tie-Up Collapses, $500 Million Stock Buyback Gets Green Light

Solstice Shares Climb 12.8% after $14.5 Billion Tie-Up Collapses, $500 Million Stock Buyback Gets Green Light

MORRIS PLAINS, New Jersey, August 29, 2026, 18:36 (EDT) – Solstice shares surged 12.8% following the termination of a $14.5 billion deal and the approval of its $500 million share repurchase plan.

  • Solstice stock gained 12.76% to close at $63.53, with trading volume reaching 16.47 million shares.
  • The companies called off their $14.5 billion merger, with no termination fees involved.
  • Solstice approved a $500 million share repurchase and kept its 2026 forecast unchanged.
  • The surge increased market value by approximately $1.15 billion.

Solstice Advanced Materials, Inc. (NASDAQ: SOLS) surged 12.76% on Friday after it cancelled its proposed purchase of Element Solutions. Shares ended at $63.53, valuing the company at roughly $10.13 billion.

The increase surpassed the amount of the newly approved share repurchase. Friday’s advance lifted equity value by about $1.15 billion, exceeding double the $500 million authorized for buybacks.

The gap reflects relief from sidestepping financing and integration risks. The deal, now cancelled, had an enterprise value of nearly $14.5 billion and was set to roughly double Solstice’s size.

Solstice and Element Solutions Inc. (NYSE: ESI) referenced shareholder input supporting separate paths. No termination fees are required from either party SEC filing.

Investor measureValueRead-through
Solstice Friday close$63.53, +12.76%Strongest short-term indicator
Volume16.47 millionRoughly 5.2 times the 65-day average
Market value addedAbout $1.15 billion2.3 times buyback authorization
Buyback authorization$500 millionRepresents 4.9% of current market value
Repurchase capacity at closeAbout 7.87 million sharesApproximately 5.0% of outstanding shares
Terminated merger value$14.5 billionEquals 1.4 times Solstice’s market cap
Element Solutions Friday move−4.38%Alternative valuation adjusted
Market figures use the August 28 close; repurchase capacity assumes the full authorization at $63.53.

Chairman Rajeev Gautam stated that Solstice appreciates input from shareholders and their “excitement about Solstice’s strategy and growth trajectory.” The board determined that maintaining independence remains the preferred path company announcement.

The buyback has the potential to boost per-share performance, though it represents an authorization instead of a guarantee. The company’s eventual purchases will be influenced by factors such as price, liquidity, and capital requirements.

Solstice’s foundational growth provides the board flexibility. Second-quarter sales climbed 11% to $1.148 billion, with net income up 23% at $119 million.

Adjusted EBITDA increased by 2% to reach $290 million. The margin declined by 218 basis points to 25.3%, indicating that higher demand did not translate into proportional profit leverage.

Sales of Electronic Materials rose by 15%, while revenue from nuclear operations grew by 27%. These segments connect Solstice with semiconductor capacity, data center cooling, and services related to nuclear fuel.

Free cash flow for the first half totaled $248 million. At the end of June, cash was close to $750 million, with long-term debt at $2.0 billion and net leverage at roughly 1.3 times second-quarter results.

Management reiterated its full-year sales forecast, projecting between $4.125 billion and $4.185 billion. The company also kept adjusted EBITDA guidance unchanged, expecting it to range from $1.035 billion to $1.055 billion.

The market value is now roughly 9.7 times the midpoint of the adjusted EBITDA outlook. The valuation keeps execution risk elevated even as the merger’s financing strain is lifted.

Risks persist. The pace of margin improvement hinges on the timing of plant turnarounds, as well as the mix and pricing of refrigerants. Meanwhile, the share buyback may vie with $420 million to $440 million in planned capital expenditures.

Friday’s decision represents a capital-return commitment exceeding $500 million. Following the rejection of an acquisition valued higher than its market capitalization, investors reevaluated Solstice as a streamlined and more specialized operator Reuters.

Solstice Advanced Materials · NASDAQ: SOLS

Deal risk removed, execution risk remains

Market close: August 28, 2026, 16:00 EDT
Company data through August 27–28, 2026
Friday close
$63.53
+12.76%
Volume
16.47M
5.2× 65-day average
Market value added
$1.15B
one session
Buyback authorized
$500M
4.9% of market cap

Scale of the repricing

Buyback$0.50B
Value added$1.15B
SOLS market cap$10.13B
Terminated deal$14.5B
The rally exceeded the buyback's mechanical effect. The market added about 2.3 times the authorization, signaling relief over avoided debt, dilution and integration complexity.

Q2 2026 operating bridge

MetricResult
Net sales$1.148B · +11%
Net income$119M · +23%
Adjusted EBITDA$290M · +2%
Adjusted margin25.3% · −218 bps
Electronic Materials sales+15%
Nuclear revenue+27%

Capital and guidance

First-half free cash flow$248M
Cash$750M
Long-term debt$2.0B
Net leverage1.3×
2026 sales guidance$4.125B–$4.185B
2026 EBITDA guidance$1.035B–$1.055B
Market cap / EBITDA midpoint9.7×

Decision timeline

July 6
$14.5 billion Element transaction announced.
Aug. 27
Companies terminate the agreement with no fee.
Aug. 27
Board authorizes first $500 million repurchase.
Aug. 28
SOLS closes 12.76% higher; ESI falls 4.38%.

Key watch: whether margin recovery and cash generation support repurchases alongside $420M–$440M of planned 2026 capital spending.

Sources: Solstice Advanced Materials, SEC Form 8-K, Reuters and August 28 market data.
Mateusz Kaczmarek

Mateusz Kaczmarek is a financial and technology journalist at TS2.tech. His coverage ranges from stocks and artificial intelligence to semiconductors and developments across global markets. He graduated from the Poznań University of Economics and Business and worked in financial analysis before becoming a business journalist. Follow Mateusz Kaczmarek on Google News.

BioXcel Stock Crashes 74.8% as Teva’s $57.5 Million Bid Meets Chapter 11
Previous Story

BioXcel Stock Crashes 74.8% as Teva’s $57.5 Million Bid Meets Chapter 11

Tenon Medical Shares Edge Down 0.4% as $3 Million Placement Raises Dilution Risk
Next Story

Tenon Medical Shares Edge Down 0.4% as $3 Million Placement Raises Dilution Risk